Cover Image
市場調查報告書

全球幹細胞市場

The Global Market for Stem Cells

出版商 BCC Research 商品編碼 63236
出版日期 內容資訊 英文 179 Pages
訂單完成後即時交付
價格
Back to Top
全球幹細胞市場 The Global Market for Stem Cells
出版日期: 2016年05月24日 內容資訊: 英文 179 Pages
簡介

全球幹細胞產品市場,2015年約59億美金。該市場預計從2016年到2021年的期間中,以年複合成長率13.1%擴大,2021年達到123億美元。

本報告提供全球幹細胞市場相關調查,幹細胞研究預測,主要國家、地區現在的市場規模與成長率,支持幹細胞的重要技術的檢閱,幹細胞產業的性質與結構分析,近幾年包含M&A活動的主要企業簡介,及各國、主要治療領域的今後5年的市場預測等。

第1章 簡介

第2章 摘要

  • 定義
  • 應用
  • 研究、商業化
  • 資金
  • 市場

第3章 概要

  • 細胞
  • 幹細胞

第4章 幹細胞研究

  • 歷史
  • 細胞為基礎的治療
  • 幹細胞研究的法規
  • 幹細胞研究、製造的實用性
    • 幹細胞製造
    • 幹細胞獲得
    • 幹細胞製造的經濟學
    • 新的幹細胞製造的發展
    • 分離、工程
    • 幹細胞銀行
    • ISCBI計劃
    • 未來展望:組織體的崛起

第5章 幹細胞的應用

  • 再生醫療
  • 目前幹細胞治療應用
    • 癌症
    • 肌肉萎縮性側索硬化症(ALS)
    • 帕金森氏症
    • 脊髓損傷
    • 老年癡呆症
    • 中風
    • 心臟病
    • 週邊動脈疾病
    • 第一型糖尿病
    • 整形外科修復
    • 肝功能衰竭
    • 移植物抗宿主病(GVHD)
    • 肺部疾病
    • 幹細胞臨床實驗狀況

第6章 幹細胞的專利

  • 專利的一般背景
  • 幹細胞的專利
  • 各國家政策
    • 美國
    • 加拿大
    • 英國
    • 德國
    • 日本
    • 中國
    • iPS細胞

第7章 幹細胞市場

  • 幹細胞市場
    • 市場成長的促進要素
    • 癌症
    • 心臟疾病
    • 中樞神經系統疾病
    • 糖尿病
    • 骨骼系
  • 全球市場的估計、預測
  • 各地各國的市場分析

第8章 企業簡介

第9章 用語

第10章 關注的幹細胞研究專利

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO035F

The global stem cell market reached over $5.9 billion in 2015 and will grow from about $6.7 billion in 2016 to nearly $12.3 billion in 2021, registering a compound annual growth rate (CAGR) of 13.1% from 2016 through 2021.

This report provides:

  • An overview of the global market for stem cells and related technologies
  • Analyses of global market trends, with data from 2014, 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021
  • Information on the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market
  • A look at the regulatory environment, healthcare policies, demographics, and other factors directly affecting stem cell-related markets
  • Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Examination of strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market
  • Profiles of major players in the industry

REPORT SCOPE

SCOPE OF REPORT

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

ANALYST'S CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the stem cell marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • DEFINITIONS
  • APPLICATIONS
  • RESEARCH AND COMMERCIALIZATION
  • FUNDING
  • MARKET
  • SUMMARY TABLE GLOBAL STEM CELL MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL STEM CELL MARKET BY REGION, 2014-2021 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • CELLS
  • STEM CELLS
  • FIGURE 1 EARLY DEVELOPMENT OF EMBRYO
    • INDUCED PLURIPOTENT STEM CELLS
      • Mesenchymal Stem Cells
        • hpSCS
    • THE CANCER PROBLEM
    • CANCER STEM CELLS-A WIDER TOPIC

CHAPTER 4 STEM CELL RESEARCH

  • HISTORY
    • EMBRYONIC STEM CELLS
      • Growth and Identification of ESCs
      • Stimulating ESCs to Differentiate
    • NEW CELL LINE
    • ADULT STEM CELLS
      • Mesenchymal Stem Cells (MSCs)
      • Hematopoietic Stem Cells (HSCs)
      • Neural Stem Cells (NSCs)
      • Endothelial Progenitor Cells (EPCs)
      • Epithelial Stem Cells (ESCs)
      • Very Small Embryonic-Like Cells (VSELs)
    • CORD BLOOD STEM CELLS
    • INDUCED PLURIPOTENT STEM CELLS (IPSCS)
      • Nuclear Reprogramming
  • CELL-BASED THERAPEUTICS
    • EMBRYONIC-DERIVED STEM CELLS
    • ADULT/PROGENITOR-DERIVED STEM CELLS
    • ENGINEERED SCS FOR TRANSPLANTATION
    • THERAPEUTIC STEM CELL BANKING
    • STEM CELL-BASED BIOMEDICAL RESEARCH
  • REGULATION OF STEM CELL RESEARCH
    • NATIONAL REGULATORY MEASURES
      • Australia
      • Brazil
      • Canada
      • China
      • France
      • Germany
      • India
      • Ireland
      • Israel
      • Italy
      • Japan
      • South Korea
      • Spain
      • Sweden
      • United Kingdom
      • United States
        • California
        • Massachusetts
        • Michigan
        • New Jersey
        • New York
      • FDA Approach
    • EUROPEAN UNION
  • PRACTICALITIES OF STEM CELL RESEARCH AND PRODUCTION
    • STEM CELL PRODUCTION
    • STEM CELL ACQUISITION
      • Characterization and Expansion
      • Maintenance and Storage
    • STEM CELL PRODUCTION ECONOMICS
      • Customized Therapy
      • Banks
    • NOVEL STEM CELL PRODUCTION DEVELOPMENTS
    • ISOLATION AND ENGINEERING
      • Adult Stem Cells
      • Embryonic Stem Cells
      • Induced Pluripotent Stem Cells
    • STEM CELL BANKING
    • ISCBI PROJECT
    • TABLE 1 COUNTRIES ENGAGED IN THE ISCBI PROGRAM
    • FUTURE PERSPECTIVE: THE RISE OF THE ORGANOIDS

CHAPTER 5 STEM CELL APPLICATIONS

  • REGENERATIVE MEDICINE
  • CURRENT APPLICATIONS OF STEM CELL THERAPY
    • CANCER
      • Hematopoiesis (Blood Cell Formation)
    • AMYOTROPHIC LATERAL SCLEROSIS
    • PARKINSON'S DISEASE
    • SPINAL CORD INJURY
    • ALZHEIMER'S DISEASE
    • STROKE
    • HEART DISEASE
      • Doubts Expressed
    • PERIPHERAL ARTERIAL DISEASE
    • TYPE 1 DIABETES
    • ORTHOPEDIC REPAIR
    • LIVER FAILURE
    • GRAFT-VERSUS-HOST DISEASE
    • LUNG DISEASE
    • STATUS OF STEM CELL CLINICAL TRIALS
      • Prochymal-stem Cell Therapy
        • Prochymal-Crohn's Disease and Gastrointestinal Injury from Radiation
      • Mesenchymal Precursor Cell (MPC) Product-Stem Cell Therapy (Orphan Drug)
      • MyoCell-Stem Cell Therapy
      • ixmyelocel-T-Stem Cell Therapy (Fast Track)
      • StemEx (carlecortemcel-L)-Stem Cell Therapy (Orphan Drug) (Fast Track)
      • GSK 2696273-Stem Cell Therapy
      • Adult Autologous Stem Cell Therapy (Renew)-Stem Cell Therapy

CHAPTER 6 STEM CELL PATENTS

  • GENERAL BACKGROUND ON PATENTS
  • STEM CELL PATENTS
    • PATENTABILITY OF STEM CELL LINES
  • INDIVIDUAL COUNTRY POLICIES
    • UNITED STATES
    • CANADA
      • EPC
    • UNITED KINGDOM
    • GERMANY
    • JAPAN
    • CHINA
      • iPS Cells
      • TABLE 2 IPS-RELATED PATENTS (YAMANAKA, 2011)
      • TABLE 3 CLASSIFICATION OF STEM CELL PATENTS

CHAPTER 7 STEM CELL MARKETS

  • MARKETS FOR STEM CELLS
    • MARKET DRIVERS
      • Healthcare
      • TABLE 4 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
      • Market Restraints
      • Biotechnology
      • Pharmaceutical
  • MARKET OPPORTUNITIES BY THERAPEUTIC CLASS
    • CANCER
      • Other Cancers
    • CARDIOVASCULAR DISEASE
      • Myocardial Infarction
      • TABLE 5 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
    • CENTRAL NERVOUS SYSTEM DISEASE
      • Spinal Cord Injury (SCI)
      • TABLE 6 STATISTICS FOR SCI IN THE U.S., 2014
      • Neurodegenerative Diseases
      • TABLE 7 NEURODEGENERATIVE DISEASES WORLDWIDE, 2015
    • DIABETES MELLITUS
    • TABLE 8 STATISTICS FOR DIABETES IN THE U.S., 2014
    • TABLE 9 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES, THROUGH 2021 ($ BILLIONS)
    • SKELETAL SYSTEM
  • GLOBAL MARKET ESTIMATES AND FORECASTS
  • TABLE 10 GLOBAL STEM CELL MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • REGIONAL AND NATIONAL MARKET ANALYSIS
    • AMERICAS
    • TABLE 11 AMERICAS STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
      • U.S.
      • TABLE 12 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES
      • TABLE 13 U.S. STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 14 U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 15 U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Canada
      • TABLE 16 CANADA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 17 CANADA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 18 CANADA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Brazil
      • TABLE 19 BRAZIL STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 20 BRAZIL STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 21 BRAZIL STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Mexico
      • TABLE 22 MEXICO STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 23 MEXICO STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
    • EUROPE
    • TABLE 24 EUROPE STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
      • Market Opportunities by Disease Category
      • TABLE 25 STATISTICS FOR CVD IN EUROPE, 2012
      • TABLE 26 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES)
      • TABLE 27 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013
      • TABLE 28 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
      • TABLE 29 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN COUNTRIES, 2013
      • France
      • TABLE 30 FRANCE STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 31 FRANCE STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 32 FRANCE STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Germany
      • TABLE 33 GERMANY STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 34 GERMANY STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 35 GERMANY STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Italy
      • TABLE 36 ITALY STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 37 ITALY STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 38 ITALY STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • Spain
      • TABLE 39 SPAIN STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 40 SPAIN STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 41 SPAIN STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • United Kingdom
      • TABLE 42 U.K. STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 43 U.K. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 44 U.K. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
    • ASIA
      • Market Opportunities by Disease Category
      • TABLE 45 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
      • TABLE 46 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES
      • TABLE 47 ASIA STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
      • Japan
      • TABLE 48 JAPAN STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 49 JAPAN STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 50 JAPAN STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • China
      • TABLE 51 CHINA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 52 CHINA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 53 CHINA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • India
      • TABLE 54 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA
      • TABLE 55 INDIA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 56 INDIA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
      • TABLE 57 INDIA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
    • REST OF WORLD
    • TABLE 58 REST OF WORLD STEM CELL MARKET BY SEGMENT, THROUGH 2021 ($ MILLIONS)

CHAPTER 8 COMPANY PROFILES

  • 3DMATRIX
  • ALDAGEN INC.
  • ANGIOBLAST SYSTEMS
  • ARTERIOCYTE
  • ATHERSYS INC.
  • BEIKE BIOTECHNOLOGY CO. LTD.
  • BIOTIME INC.
  • BRAINSTORM CELL THERAPEUTICS INC.
  • CALADRIUS BIOSCIENCES INC.
  • CAPRICOR INC.
  • CELLERANT THERAPEUTICS INC.
  • CELLERIX SA
  • CELLULAR DYNAMICS INTERNATIONAL
  • CELYAD
  • CLONTECH
  • CYTORI THERAPEUTICS INC.
  • EPISTEM LTD.
  • GAMIDA CELL LTD.
  • GLOBALSTEM
  • HYBRID ORGAN GMBH
  • INTELLICELL BIOSCIENCES INC.
  • INTERNATIONAL STEM CELL CORP.
  • JUVENTAS THERAPEUTICS INC.
  • MESOBLAST LTD.
  • NEURALSTEM
  • NEUROGENERATION
  • OCATA
  • OSIRIS THERAPEUTICS INC.
  • PRIMEGEN BIOTECH LLC
  • RENEURON GROUP
  • RHINOCYTE INC.
  • STEM CELLS INC.
  • STEMCELL TECHNOLOGIES SARL
  • STEM CELL THERAPEUTICS CORP.
  • STEMEDICA CELL TECHNOLOGIES INC.
  • STEMINA BIOMARKER DISCOVERY INC.
  • STEMPEUTICS RESEARCH PVT. LTD.
  • TIGENIX NV
  • U.S. STEM CELL
  • VERASTEM INC.
  • VERICEL
  • VERISTEM TECHNOLOGIES
  • VIACYTE
  • VITRO DIAGNOSTICS INC.
  • WICELL RESEARCH INSTITUTE
  • XPAND BIOTECHNOLOGY BV

CHAPTER 9 GLOSSARY

CHAPTER 10 SIGNIFICANT STEM CELL RESEARCH PATENTS

  • TABLE 59 SIGNIFICANT STEM CELL RESEARCH PATENTS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL STEM CELL MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 COUNTRIES ENGAGED IN THE ISCBI PROGRAM
  • TABLE 2 IPS-RELATED PATENTS (YAMANAKA, 2011)
  • TABLE 3 CLASSIFICATION OF STEM CELL PATENTS
  • TABLE 4 HEALTHCARE SYSTEMS OF DIFFERENT COUNTRIES
  • TABLE 5 EXAMPLES OF COMPANIES DEVELOPING STEM CELL THERAPIES FOR CVD
  • TABLE 6 STATISTICS FOR SCI IN THE U.S., 2014
  • TABLE 7 NEURODEGENERATIVE DISEASES WORLDWIDE, 2015
  • TABLE 8 STATISTICS FOR DIABETES IN THE U.S., 2014
  • TABLE 9 GLOBAL MARKET FOR DIABETES MELLITUS TREATMENTS AND DEVICES, THROUGH 2021 ($ BILLIONS)
  • TABLE 10 GLOBAL STEM CELL MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 11 AMERICAS STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
  • TABLE 12 POTENTIAL U.S. PATIENT POPULATIONS FOR CELL-BASED THERAPIES
  • TABLE 13 U.S. STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 14 U.S. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 15 U.S. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 16 CANADA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 17 CANADA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 18 CANADA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 19 BRAZIL STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 20 BRAZIL STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 21 BRAZIL STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 22 MEXICO STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 23 MEXICO STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 EUROPE STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
  • TABLE 25 STATISTICS FOR CVD IN EUROPE, 2012
  • TABLE 26 RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2012 (NO. OF DEATHS PER 100,000 CASES)
  • TABLE 27 STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2013
  • TABLE 28 STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT EUROPEAN COUNTRIES, 2011
  • TABLE 29 PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN COUNTRIES, 2013
  • TABLE 30 FRANCE STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 FRANCE STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 FRANCE STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 GERMANY STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 GERMANY STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 GERMANY STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 ITALY STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 37 ITALY STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 ITALY STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 39 SPAIN STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 40 SPAIN STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 41 SPAIN STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 42 U.K. STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 43 U.K. STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 44 U.K. STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 45 STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
  • TABLE 46 EXAMPLES OF STEM CELL POLICIES IN ASIAN COUNTRIES
  • TABLE 47 ASIA STEM CELL MARKET BY COUNTRY, THROUGH 2021 ($ MILLIONS)
  • TABLE 48 JAPAN STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 49 JAPAN STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 50 JAPAN STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 51 CHINA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 52 CHINA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 53 CHINA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 54 POTENTIAL CANDIDATES FOR STEM CELL THERAPY IN INDIA
  • TABLE 55 INDIA STEM CELL THERAPY MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 56 INDIA STEM CELL RESEARCH AND SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 57 INDIA STEM CELL CORD BLOOD SERVICES MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 58 REST OF WORLD STEM CELL MARKET BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 59 SIGNIFICANT STEM CELL RESEARCH PATENTS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL STEM CELL MARKET BY REGION, 2014-2021 ($ MILLIONS)
  • FIGURE 1 EARLY DEVELOPMENT OF EMBRYO
Back to Top